Washington has rejected plans to revamp vaccine preparedness for decades and repeatedly paid a price. The Biden administration is at a similar crossroads.
A 50-microgram dose increased antibodies by roughly 37-fold, and a full dose of 100 micrograms was even more powerful, the company said.
Wall Street’s unease continued after Moderna’s chief executive said there could be a “material drop” in the effectiveness of current vaccines against the new variant.
South Africa gave the world an early warning. Decisive action on containment and surveillance could help us control it.
If the C.D.C. agrees, adults who received a second shot of the Pfizer or Moderna vaccine at least six months ago could be eligible by this weekend.
The Biden administration will spend billions of dollars on a new plan to combat the pandemic, investing in antiviral pills, rapid tests and manufacturing.
Moderna’s patent application names several employees as the sole inventors of a crucial component of its coronavirus vaccine, excluding three government scientists.
The latest data is reassuring. Myocarditis remains very uncommon, and it is almost always mild and temporary. The heart risk from Covid-19 itself is far greater.
Moderna’s shots have previously gone almost entirely to wealthier countries.
The results were announced a day before an advisory committee of the Food and Drug Administration is scheduled to review data for the Pfizer-BioNTech vaccine in children 5 through 11.
“In our hearts, I think people don’t quite agree with this notion of a booster dose,” said one leading vaccine expert.
Recipients of the Moderna and the J.&J. vaccines may receive extra doses, although the shots continue to prevent illness and death.
The agency will also allow vaccine recipients to pick which vaccine they want as a booster, endorsing a mix-and-match approach.
The F.D.A. may authorize booster shots of vaccines different from the ones that Americans originally received. The science behind the move is promising.
The agency may act this week, when it is expected to authorize booster shots for recipients of the Moderna and Johnson & Johnson vaccines.
But many panel members said J. & J. recipients might also benefit from the option of a Pfizer-BioNTech or Moderna booster, an action that an F.D.A. official said was possible.
Confused about who can get a booster shot of which vaccine, and what the F.D.A.’s advisers on vaccines are voting on this week? This scorecard may help.
Those eligible for the extra shot would include adults over 65 and others at high risk — the same groups now eligible for a Pfizer-BioNTech boost
People who have received the company’s one-shot vaccine may benefit from a booster with another brand. F.D.A. advisers will discuss the data on Friday.
The debate over gifted-and-talented programs. Also: Moderna’s chairman responds; “illiberal democracy” in Hungary – and the U.S.?
Some poorer countries are paying more and waiting longer for the company’s vaccine than the wealthy — if they have access at all.
A series of studies found that the Moderna vaccine seemed to be more protective over the long term than the Pfizer-BioNTech vaccine. Here’s why.
Moderna accepted $2.5 billion in taxpayer money to develop its Covid-19 vaccine. But officials in the U.S. and overseas are having trouble persuading the company to license its technology.
Vaccinated kids aged 5 to 11 showed evidence of protection against the virus, the company said. The data must be reviewed by the F.D.A. before children can be inoculated.
The committee said there was insufficient evidence to recommend third shots for all adult recipients of the vaccine, as Pfizer had requested.
A week before President Biden’s plan is to roll out, scientists are at odds about whether extra coronavirus shots are needed and for whom.
An article, written with other vaccine experts, put the regulators at odds with key federal health officials, including Dr. Anthony S. Fauci.
As rich countries ponder the marginal utility of third doses, billions of people around the world are still waiting for their first.
Federal regulators warned on Thursday they may not have enough data to recommend boosters for anyone except certain recipients of the Pfizer vaccine by late September.
With expectations that interest rates will stay down and government spending will stay up, the stock market has learned to live with the pandemic, even as cases increase.
The White House played down the president’s remarks, saying the administration had not changed its original proposal to administer a third shot to most vaccinated adults eight months after the second.
Congress appropriated $16 billion to ramp up Covid-19 countermeasures, but a new report found that the Biden administration had spent very little of it on expanding vaccine manufacturing capacity.
Health experts say that boosters are likely to be needed eventually and that more data should be available in the next several weeks.
Federal health officials said the new data justified a campaign of booster shots. But some scientists disagreed, saying not every American needs another dose.
One of the most vaccinated societies, Israel now has one of the highest infection rates in the world, raising questions about the vaccine’s efficacy.
Nursing home residents and health care workers will most likely be the first to get booster shots, as soon as September, followed by other older people who were vaccinated last winter.
The Food and Drug Administration’s move is expected to kick off more vaccination mandates for hospital workers, college students and federal troops.
My office reopened at the height of the pandemic. We’ve thrived.
The growing consensus that at least some Americans will need a booster is partly tied to research suggesting that Pfizer’s vaccine is less effective after about six months.
Many who received the shot may need to consider boosters, the authors said. But federal health officials do not recommend second doses.
France is handing out third shots of the two-dose vaccines to cancer patients and others with immune system impairments. In the United States, patients like these are on their own.
The vaccine also produced long-lasting immune responses, researchers said. Booster shots seem unnecessary, at least for now.
A shipment to Pakistan was part of a new phase of the administration’s pandemic response: a round-the-clock effort to clear regulatory and logistical hurdles to share doses with countries in need.
New scientific research underscores the effectiveness of vaccines and their versatility in the fight against the coronavirus.
Immune cells are still organizing to fight the coronavirus months after inoculation, scientists reported.
Several countries are allowing mix-and-match inoculation, which scientists hope will have benefits, and Chancellor Angela Merkel of Germany is among those to get it.
Important immune cells survive in the bone marrow of people who were infected with the virus or were inoculated against it, new research suggests.
The U.S., which has a surplus of vaccines, could soon have two options for teens while many countries face shortages.
Mobile Covid-19 vaccine clinics in vans and buses are rolling up to neighborhoods in Delaware, Minnesota and Washington State to reach people who have been unable to travel to vaccination centers.
The island’s border controls had shielded it from the worst of the pandemic. But new variants and a slow vaccine rollout gave the virus an opening.